Drugs / FALNIDAMOL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003980 | Feb 1999 → ? | cancer of unknown primary site | European Organisation for Research and Treatment of Cancer - EORTC | Suspended | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FALNIDAMOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL258940 ↗ |
| Known as | BIBX 1382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003980 ↗ |
| Action | Inhibit | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL258940 ↗ |
| Modality | Small molecule | — CHEMBL258940 ↗ |
| Route | Intravenous | “Patients receive BIBX 1382 IV over 1 hour” NCT00003980 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL258940 ↗ |